Fingolimod treatment after natalizumab-related progressive multifocal leukoencephalopathy: three new cases

Mult Scler. 2015 Apr;21(5):671-2. doi: 10.1177/1352458514549823. Epub 2014 Oct 10.

Authors

Delphine Peaureaux¹, Beatrice Pignolet², Damien Biotti¹, Florence Bucciarelli², Jana Gaina¹, Cristina Bucur¹, Michel Clanet², Guillaume Martin-Blondel³, David Brassat⁴

Affiliations

¹ Pole des neurosciences CHU Toulouse, France.
² Pole des neurosciences CHU Toulouse, France INSERM UMR 1043 et Université de Toulouse; UPS; France.
³ INSERM UMR 1043 et Université de Toulouse; UPS; France Pole spécialités médicales et pathologies infectieuses, CHU Toulouse, France.
⁴ Pole des neurosciences CHU Toulouse, France INSERM UMR 1043 et Université de Toulouse; UPS; France dbrassat@yahoo.fr.

PMID: 25305251
DOI: 10.1177/1352458514549823

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Female
Fingolimod Hydrochloride / therapeutic use*
Humans
Immunologic Factors / adverse effects*
Immunologic Factors / therapeutic use
Immunosuppressive Agents / therapeutic use*
JC Virus
Leukoencephalopathy, Progressive Multifocal / chemically induced*
Leukoencephalopathy, Progressive Multifocal / drug therapy*
Male
Multiple Sclerosis, Relapsing-Remitting / complications*
Multiple Sclerosis, Relapsing-Remitting / drug therapy
Natalizumab / adverse effects*
Natalizumab / therapeutic use

Substances

Immunologic Factors
Immunosuppressive Agents
Natalizumab
Fingolimod Hydrochloride